CGC Earnings

CGC reported its earnings on 2026-06-15, showcasing a revenue of 71.25M against an estimate of 74.36M, resulting in a -4.18% surprise. The EPS was -0.17, surpassing the expected -0.06 by -183.33%. The stock experienced a -1.71% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following CGC's earnings announcement on 2026-06-15, the stock price moved by -1.71% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, CGC's stock price tends to shift by an average of 7.85% in the 10 days leading up to earnings and -3.09% in the 10 days following, providing insight into potential market.

For 2027/Q1, analysts estimate CGC's annual revenue to reach 68.95M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CGC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CGC's stock price typically moves by 7.85% in the 10 days before its earnings and -3.09% in the 10 days after. For the upcoming 2027/Q1 earnings, analysts expect an EPS of -0.04 and revenue of 68.95M.

The earnings call presents a mixed picture: positive elements include a 22% increase in international cannabis revenue and reduced SG&A expenses. However, concerns arise from declining gross margins and unclear guidance on achieving positive EBITDA. The Q&A reveals uncertainties about veteran pricing impacts and cash utilization. The absence of a clear market cap further complicates predictions. Overall, the sentiment is balanced, resulting in a neutral outlook for the stock price movement over the next two weeks.